$MURA News
Last published 11mo ago
- 11mo agoMURAXOMAXOMAOXOMAPXOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plcGlobeNewswireEMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced
- 11mo agoMURAXOMAMural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionGlobeNewswireWALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the
- 11mo agoMURAXOMAMural Oncology Announces Sanction of the Scheme by the High CourtGlobeNewswireWALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its
- 11mo agoMURAXOMAMural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyGlobeNewswireWALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between XOMA Royalty
- 1y agoMURAXOMAMural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA RoyaltyGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION WALTHAM, Mass.
- 1y agoMURAXOMAMural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General MeetingGlobeNewswireWALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural"), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel
- 1y agoMURAXOMAMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per ShareGlobeNewswireWALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation
- 1y agoMURAMural Oncology Announces Second Quarter Financial Results and Provides Business UpdateGlobeNewswireMural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by
- 1y agoMURAMural Oncology Announces Plans to Explore Strategic AlternativesGlobeNewswireFollowing review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash
- 1y agoMURAMural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerGlobeNewswireBased on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability profile generally
- 1y agoMURAMural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical MilestonesGlobeNewswireInterim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of potentially
- 1y agoMURAMural Oncology to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireWALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways,
- 1y agoMURAMural Oncology Highlights Pipeline Progress and Anticipated 2025 CatalystsGlobeNewswireReadouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary data readouts for
- 1y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address
- 1y agoMURAMural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of CancerGlobeNewswireNemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily pretreated advanced
- 1y agoMURAMural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline ProgressGlobeNewswireCompany remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma
- 2y agoMURAMural Oncology to Participate in Two Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
- 2y agoMURAMural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewswireLess frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation
- 2y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address
- 2y agoMURAMural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewswireWALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address
- 2y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
- 2y agoMURAMural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical ProgressGlobeNewswireKey data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management
- 2y agoMURAMural Oncology Strengthens Board of Directors with the Appointment of Sachiyo MinegishiGlobeNewswireWALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
- 2y agoMURAMural Oncology to Host First Virtual Investor Day on September 26, 2024GlobeNewswireCompany will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the potential of new
- 2y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
- 2y agoMURAMural Oncology to Present at Two Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
- 2y agoMURAMural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline ProgressGlobeNewswireCompany remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On track to report
- 2y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
- 2y agoMURAMural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of DirectorsGlobeNewswireWALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address
- 2y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass. and DUBLIN, July 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
- 2y agoMURAMural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor ConferenceGlobeNewswireWALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
- 2y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass. and DUBLIN, June 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
- 2y agoMURAMural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual MeetingGlobeNewswireARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural's late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally
- 2y agoMURAMural Oncology Announces First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireMural's lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expected in 1H 2025 A
- 2y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass and DUBLIN, May 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering
- 2y agoMURAMural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireWALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed
- 2y agoMURAMural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual MeetingGlobeNewswireFor the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance with additional
- 2y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass. and DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein
- 2y agoMURAMural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateGlobeNewswireLead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2025 Newly
- 2y agoMURAMural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireDUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas
- 2y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to
- 2y agoMURAMural Oncology to Present at the TD Cowen 44th Annual Health Care ConferenceGlobeNewswireDUBLIN, Ireland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of
- 2y agoMURAMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to
- 2y agoMURAMural Oncology Announces Enhancements to Late-Stage Clinical TrialsGlobeNewswireStrategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful data Mural intends to nominate development candidates for its
- 2y agoMURAMural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine ImmunotherapiesGlobeNewswireMural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company's lead product candidate – nemvaleukin alfa – being developed to treat a wide